Thanks to the pioneering new blood test, lung cancer could be detected earlier. This news comes as a fresh hope for lung cancer patients. The main reason behind the increasing number of complications in lung cancer treatment is its detection at a later stage. Lung cancer usually has mild to no symptoms at an early stage and thus, often gets detected later. This new lung cancer test helps to improve lung cancer detection rates.
Research has been developed by the University of Nottingham along with support from St Andrews University which has revealed that taking EarlyCDT-Lung blood test resulted in 36% reduction in late stage lung cancer diagnosis as compared to standard clinical practice. This breakthrough could lead to early intervention, and saving lives. The EarlyCDT-Lung test was able to detect whether an individual’s immune system had produced antibodies against cancer antigens, which were detected in their blood. If the result of test was positive, the participants were scheduled to have CT scans of chest every six months for two years unless lung cancer was diagnosed within that period.
Professor John Robertson, whose research at the University of Nottingham helped lead to the breakthrough, said: “The EarlyCDT-Lung blood test, which is commercially available through Oncimmune, is the result of more than two decades of research from a creative idea through laboratory research, product development and randomised clinical trial.” “It was very satisfying to see it being supported in the NICE review earlier this year and to follow its increasing use in many countries across the world for the early detection of lung cancer,” he added.
This trial is first of its kind carried out across the world and could revolutionize lung cancer treatment.
The information shared in this blog is for educational purposes only and is not a substitute for medical advice.